SYP and prostate carcinoma: We retrospectively reviewed all 8,194 prostate cancer cases with available immunohistochemistry reports and found 2.3% (n = 189) with any one of the NE markers (CHGA, SYP, and NCAM1) being positive in at least 5% of epithelial cells.